Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Ductal, Breast | 7 | 2024 | 1099 | 0.400 |
Why?
|
| Breast Neoplasms | 18 | 2024 | 21207 | 0.360 |
Why?
|
| Sentinel Lymph Node Biopsy | 6 | 2022 | 737 | 0.350 |
Why?
|
| Carcinoma, Lobular | 4 | 2019 | 480 | 0.290 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 4 | 2024 | 934 | 0.290 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2016 | 260 | 0.210 |
Why?
|
| Genes, BRCA1 | 3 | 2000 | 755 | 0.180 |
Why?
|
| Lymph Node Excision | 4 | 2022 | 1271 | 0.160 |
Why?
|
| Mastectomy | 2 | 2018 | 1862 | 0.160 |
Why?
|
| Axilla | 4 | 2022 | 623 | 0.150 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2001 | 1062 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1997 | 275 | 0.140 |
Why?
|
| Arabidopsis Proteins | 1 | 1998 | 261 | 0.140 |
Why?
|
| Mammography | 2 | 2024 | 2433 | 0.130 |
Why?
|
| Lymph Nodes | 3 | 2022 | 3474 | 0.130 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1997 | 414 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1997 | 458 | 0.120 |
Why?
|
| Neoplasm Proteins | 4 | 2001 | 3604 | 0.120 |
Why?
|
| Germ-Line Mutation | 5 | 2000 | 1885 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 1015 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 2907 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2001 | 2810 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2018 | 1502 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 4 | 2024 | 3620 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2360 | 0.080 |
Why?
|
| Breast | 3 | 2021 | 1976 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2019 | 2783 | 0.070 |
Why?
|
| Ovarian Neoplasms | 3 | 2000 | 4916 | 0.070 |
Why?
|
| Neoplasm Staging | 6 | 2022 | 11244 | 0.070 |
Why?
|
| Mammaplasty | 1 | 2016 | 1269 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2000 | 12171 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5107 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 2914 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3556 | 0.050 |
Why?
|
| Hyperplasia | 2 | 2021 | 1151 | 0.050 |
Why?
|
| Arylsulfotransferase | 1 | 2000 | 27 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 9419 | 0.040 |
Why?
|
| BRCA2 Protein | 3 | 2000 | 802 | 0.040 |
Why?
|
| Female | 20 | 2024 | 397187 | 0.040 |
Why?
|
| Alleles | 3 | 2000 | 6894 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 2022 | 381 | 0.040 |
Why?
|
| RNA, Neoplasm | 2 | 2001 | 749 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2001 | 1623 | 0.040 |
Why?
|
| Genes, APC | 1 | 1999 | 145 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11878 | 0.040 |
Why?
|
| Mind-Body Therapies | 1 | 2021 | 294 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 1034 | 0.040 |
Why?
|
| Genes, erbB-2 | 1 | 1998 | 162 | 0.040 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 59626 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2001 | 17623 | 0.040 |
Why?
|
| Penetrance | 1 | 1999 | 385 | 0.040 |
Why?
|
| Genes, myc | 1 | 1998 | 391 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 1999 | 213 | 0.030 |
Why?
|
| Base Sequence | 2 | 1998 | 12422 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 8542 | 0.030 |
Why?
|
| Codon | 1 | 1998 | 599 | 0.030 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 1997 | 115 | 0.030 |
Why?
|
| Exons | 2 | 2000 | 2394 | 0.030 |
Why?
|
| Plant Proteins | 1 | 1998 | 376 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1998 | 714 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2022 | 54924 | 0.030 |
Why?
|
| Genes, ras | 1 | 1998 | 663 | 0.030 |
Why?
|
| Humans | 23 | 2024 | 768171 | 0.030 |
Why?
|
| Potassium Channels | 1 | 1998 | 538 | 0.030 |
Why?
|
| Lymphoma | 1 | 2024 | 1898 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2001 | 9540 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2000 | 788 | 0.030 |
Why?
|
| Retrospective Studies | 7 | 2024 | 81760 | 0.030 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 1999 | 388 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2001 | 952 | 0.030 |
Why?
|
| Methylene Blue | 1 | 2014 | 156 | 0.030 |
Why?
|
| Exercise | 2 | 2021 | 5954 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1997 | 1497 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39354 | 0.030 |
Why?
|
| Aged | 9 | 2024 | 171502 | 0.030 |
Why?
|
| Adult | 10 | 2024 | 223646 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2001 | 3806 | 0.030 |
Why?
|
| Breast Implants | 1 | 2016 | 414 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 1744 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2019 | 939 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 1997 | 1120 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2014 | 564 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 4249 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2019 | 2258 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 13422 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2001 | 12801 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2001 | 1553 | 0.020 |
Why?
|
| Middle Aged | 8 | 2024 | 223487 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1997 | 4120 | 0.020 |
Why?
|
| Jews | 2 | 2000 | 359 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 2956 | 0.020 |
Why?
|
| Disease Management | 1 | 2018 | 2535 | 0.020 |
Why?
|
| Gestational Age | 1 | 2016 | 3621 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 6082 | 0.020 |
Why?
|
| Cytokines | 1 | 2001 | 7452 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 30009 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2001 | 8648 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12840 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1998 | 11095 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 6124 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2019 | 10478 | 0.010 |
Why?
|
| Pregnancy | 2 | 2016 | 30255 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13677 | 0.010 |
Why?
|
| Vacuum | 1 | 2000 | 65 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2001 | 375 | 0.010 |
Why?
|
| Histidine | 1 | 2000 | 301 | 0.010 |
Why?
|
| Quality of Life | 1 | 2021 | 13490 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2000 | 766 | 0.010 |
Why?
|
| Cricetulus | 1 | 2001 | 812 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 1135 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 1379 | 0.010 |
Why?
|
| Ultrasonography, Mammary | 1 | 2000 | 243 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 1064 | 0.010 |
Why?
|
| Automation | 1 | 2000 | 589 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2000 | 553 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 2423 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2005 | 1043 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 1989 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2000 | 1648 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24318 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2748 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 2179 | 0.010 |
Why?
|
| Arginine | 1 | 2000 | 932 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1999 | 785 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 1999 | 663 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2000 | 966 | 0.010 |
Why?
|
| Genotype | 2 | 2000 | 13045 | 0.010 |
Why?
|
| Risk Factors | 2 | 2019 | 74944 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2001 | 1505 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 2828 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 3436 | 0.010 |
Why?
|
| Age Distribution | 1 | 2000 | 2873 | 0.010 |
Why?
|
| Adolescent | 2 | 2019 | 89169 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 4477 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2001 | 2732 | 0.010 |
Why?
|
| Estrogens | 1 | 2000 | 1536 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 5028 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 15833 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 3346 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 4585 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 5756 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 41753 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 3740 | 0.010 |
Why?
|
| Equipment Design | 1 | 2000 | 3522 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2000 | 1524 | 0.010 |
Why?
|
| Heterozygote | 1 | 1999 | 2798 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 60066 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2000 | 22290 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1999 | 3623 | 0.010 |
Why?
|
| Calcinosis | 1 | 2000 | 1482 | 0.010 |
Why?
|
| Pedigree | 1 | 1999 | 4539 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 5797 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 65379 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 3703 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 15453 | 0.000 |
Why?
|
| Ultrasonography | 1 | 2001 | 6004 | 0.000 |
Why?
|
| Survival Analysis | 1 | 2000 | 10099 | 0.000 |
Why?
|
| DNA Methylation | 1 | 2001 | 4428 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2001 | 19025 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 14729 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 2000 | 12543 | 0.000 |
Why?
|
| Time Factors | 1 | 2005 | 40220 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 18065 | 0.000 |
Why?
|
| Animals | 1 | 2001 | 169285 | 0.000 |
Why?
|
| Male | 1 | 1999 | 364731 | 0.000 |
Why?
|
Concepts
(165)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(41)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_